Relative Value

The Relative Value of one VY4 stock under the Base Case scenario is hidden EUR. Compared to the current market price of 1.806 EUR, SNDL Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VY4 Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
60
vs Industry
79
Median 3Y
0.7
Median 5Y
0.9
Industry
2.6
Forward
0.8
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-6
Industry
21.6
Forward
-34.8
vs History
23
vs Industry
30
Median 3Y
8.7
Median 5Y
-9.8
Industry
16.5
vs History
19
vs Industry
Median 3Y
-7.2
Median 5Y
-7.7
Industry
22.5
vs History
36
vs Industry
75
Median 3Y
0.5
Median 5Y
0.6
Industry
2.3
vs History
60
vs Industry
86
Median 3Y
0.6
Median 5Y
0.8
Industry
2.9
Forward
0.6
vs History
66
vs Industry
72
Median 3Y
2.4
Median 5Y
3.3
Industry
5.5
vs History
28
vs Industry
12
Median 3Y
13.4
Median 5Y
-13.7
Industry
13
Forward
9.7
vs History
vs Industry
Median 3Y
-12.9
Median 5Y
-13.4
Industry
16.6
Forward
-89.6
vs History
22
vs Industry
39
Median 3Y
6.9
Median 5Y
-5.9
Industry
15.8
vs History
23
vs Industry
29
Median 3Y
8.3
Median 5Y
-5.8
Industry
19.1
vs History
38
vs Industry
78
Median 3Y
0.5
Median 5Y
0.5
Industry
1.9

Multiples Across Competitors

VY4 Competitors Multiples
SNDL Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
SNDL Inc
F:VY4
464.9m EUR 0.8 -8.1 14 -54.6
US
Eli Lilly and Co
NYSE:LLY
971.9B USD 16.4 52.8 35.5 38
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
509.1B USD 5.5 20.3 16.6 21.5
CH
Roche Holding AG
SIX:ROG
255.4B CHF 4.1 27.1 11.6 13.5
UK
AstraZeneca PLC
LSE:AZN
209.2B GBP 4.8 29.8 108.3 158.5
CH
Novartis AG
SIX:NOVN
204.4B CHF 4.6 17.9 11.3 14.6
US
Merck & Co Inc
NYSE:MRK
247.4B USD 3.9 13 9.3 11
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.7 9.6 11.1
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
147B USD 2.3 15 7.6 10.4
P/E Multiple
Earnings Growth PEG
CA
SNDL Inc
F:VY4
Average P/E: 23.7
Negative Multiple: -8.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.8
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.1
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.8
38%
0.8
CH
Novartis AG
SIX:NOVN
17.9
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
15
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
SNDL Inc
F:VY4
Average EV/EBITDA: 400.1
14
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.5
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.6
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.6
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
11.3
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
2%
4.8
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
SNDL Inc
F:VY4
Average EV/EBIT: 1 881.1
Negative Multiple: -54.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.5
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.5
23%
6.9
CH
Novartis AG
SIX:NOVN
14.6
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
1%
11.1
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
8%
1.3